🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs
1,344

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,344 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 26 of 28

  1. Treatment of advanced or metastatic triple negative breast cancer with tumor infiltrating lymphocytes (TILs).

    The George Institute

    advanced or metastasic triple-negative breast cancer

    phase 1 other active

    1 trial

  2. Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)

    Disc Medicine

    Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

    phase 1 other active

    1 trial

  3. Trebananib 3 mg/kg

    Takeda

    Neoplasms, Advanced Solid

    phase 1 small molecule completed

    1 trial

  4. Trial of the novel peroral anti-tumor treatment in patients with solid tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

    phase 1 other active

    1 trial

  5. Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants with Advanced Solid Tumors

    Genmab A/S

    Advanced Malignant Solid Tumors

    phase 1 other active

    1 trial

  6. Trial to assess the safety and antitumor activity of GEN1057 on malignant solid tumors

    Genmab A/S

    Metastatic or advanced malignant solid tumors

    phase 1 other active

    1 trial

  7. Triprorelin for injection

    The First People's Hospital of Lianyungang

    Prostate Cancer (CRPC)

    phase 1 small molecule active

    1 trial

  8. Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  9. Tuvusertib (M1774) in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

    Merck Sharp and Dohme

    Metastatic or Locally Advanced Unresectable Solid Tumors

    phase 1 other active

    1 trial

  10. U96

    The First People's Hospital of Lianyungang

    Relapsed or Refractory B Cell Leukemia and Lymphoma

    phase 1 small molecule active

    1 trial

  11. UB-921

    United Therapeutics Europe Ltd

    Breast Neoplasm

    phase 1 mab completed

    1 trial

  12. UTAA09 injection

    The First People's Hospital of Lianyungang

    Recurrent or Refractory B-cell Non Hodgkin's Lymphoma

    phase 1 mab active

    1 trial

  13. Ublituximab + TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  14. Unesbulin

    PTC THERAPEUTICS, INC.

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  15. VEGF inhibitor PTC299

    PTC THERAPEUTICS, INC.

    Brain and Central Nervous System Tumors

    phase 1 small molecule completed

    1 trial

  16. VIR-5500

    Vir Biotechnology

    Hormone-refractory Prostate Cancer

    phase 1 small molecule active

    1 trial

  17. VIR-5525

    Vir Biotechnology

    Solid Tumor Malignancies

    phase 1 small molecule active

    1 trial

  18. VX15/2503

    VACCINEX, INC.

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  19. VX15/2503

    VACCINEX, INC.

    Squamous Cell Carcinoma of the Head and Neck

    phase 1 mab active

    1 trial

  20. Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    phase 1 small molecule active

    1 trial

  21. Vantictumab

    Mereo BioPharma Group plc

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  22. Vantictumab combined with paclitaxel

    Mereo BioPharma Group plc

    Metastatic Breast Cancer

    phase 1 small molecule completed

    1 trial

  23. Vemurafenib Oral Tablet [Zelboraf]

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

    phase 1 small molecule active

    1 trial

  24. Venetoclax

    Karyopharm Therapeutics Inc

    Diffuse Large B-cell Lymphoma

    phase 1 small molecule completed

    1 trial

  25. Venetoclax

    Karyopharm Therapeutics Inc

    Acute Leukemia of Ambiguous Lineage in Relapse

    phase 1 small molecule active

    1 trial

  26. Venetoclax

    Kura Oncology

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  27. Vitamin B6-restricted diet + immunotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor Cancer

    phase 1 other active

    1 trial

  28. Volasertib, low dose, d1q3w

    Boehringer Ingelheim

    Neoplasms

    phase 1 small molecule completed

    1 trial

  29. Vyxeos

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  30. WGc-0201 injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 1 mab active

    1 trial

  31. WP1220

    Moleculin Biotech

    Cutaneous T-Cell Lymphoma/Mycosis Fungoides

    phase 1 small molecule completed

    1 trial

  32. WSK-IM05 (4×10^10 vp)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HPV-positive Oropharyngeal Squamous Cell Carcinoma

    phase 1 mab active

    1 trial

  33. WT1-loaded CBDC Vaccine

    AXIM BIOTECHNOLOGIES, INC.

    AML: Acute Myeloid Leukemia/ cancer of blood and bone marrow

    phase 1 small molecule active

    1 trial

  34. WT1-sensitized T cells

    Evidence Based Cataract Study Group

    Leukemia

    phase 1 mab completed

    1 trial

  35. WTX-124

    Werewolf Therapeutics

    Metastatic Solid Tumor

    phase 1 small molecule active

    1 trial

  36. X4P-001

    X4 Pharmaceuticals, Inc

    Melanoma

    phase 1 small molecule completed

    1 trial

  37. YMN-A02 100μg

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 1 mab active

    1 trial

  38. YMN101

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Tumor

    phase 1 mab active

    1 trial

  39. Yang Yin Fu Zheng Jie Du therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 1 small molecule completed

    1 trial

  40. Z650

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Pancreatic Cancer

    phase 1 small molecule terminated

    1 trial

  41. ZG0895 Hydrochloride for Injection

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  42. ZIO-101

    Alaunos Therapeutics

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  43. ZIO-101 (Darinaparsin)

    Alaunos Therapeutics

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  44. ZIO-101 (Darinaparsin)

    Alaunos Therapeutics

    Acute Leukemia

    phase 1 small molecule completed

    1 trial

  45. ZIO-101-C (Darinaparsin)

    Alaunos Therapeutics

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  46. ZIO-101-C (Darinaparsin)

    Alaunos Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  47. ZIO-201

    Alaunos Therapeutics

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  48. ZIO-201-T and doxorubicin

    Alaunos Therapeutics

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,344 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.